+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Muscarinic M1 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Muscarinic M1 Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adenosine A1 Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Adenosine A1 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Congenital Adrenal Hyperplasia- Pipeline Insight, 2025 - Product Thumbnail Image

Congenital Adrenal Hyperplasia- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adult Growth Hormone Deficiency (AGHD) - Pipeline Insight, 2025 - Product Thumbnail Image

Adult Growth Hormone Deficiency (AGHD) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Propionic Acidemia - Pipeline Insight, 2025 - Product Thumbnail Image

Propionic Acidemia - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
GM2 Gangliosidosis - Pipeline Insight, 2025 - Product Thumbnail Image

GM2 Gangliosidosis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Hypophosphatasia - Epidemiology Forecast-2034 - Product Thumbnail Image

Hypophosphatasia - Epidemiology Forecast-2034

  • Report
  • December 2024
  • 68 Pages
  • Global
From
Menkes Disease - Epidemiology Forecast - 2034 - Product Thumbnail Image

Menkes Disease - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 53 Pages
  • Global
From
Antiphospholipid Syndrome (APS) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Antiphospholipid Syndrome (APS) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 79 Pages
  • Global
From
Prader-Willi Syndrome - Epidemiology Forecast - 2034 - Product Thumbnail Image

Prader-Willi Syndrome - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 80 Pages
  • Global
From
Diabetic Kidney Disease (DKD) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Diabetic Kidney Disease (DKD) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 95 Pages
  • Global
From
Semaglutide Market Size, Emerging Insight, and Forecast to 2032 - Product Thumbnail Image

Semaglutide Market Size, Emerging Insight, and Forecast to 2032

  • Report
  • December 2024
  • 30 Pages
  • Global
From
From
From
From
From
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more